News

An innovative computational approach for identifying new alpha-synuclein tracer molecules could be used to track the progression of Parkinson’s disease, according to a recent study. The study, “Identification of a nanomolar affinity α-synuclein fibril imaging probe by ultra-high throughput in silico…

A new compound called CLR01, which works like a “molecular tweezer” to clear toxic protein clumps that accumulate in brain cells, could become a promising therapy to slow Parkinson’s disease progression, a study suggests. The study, “CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson’s…

Previous falls, hallucinations, and cognitive problems are among the factors that predict a risk of recurrent falls in elderly people with parkinsonian gait, a study suggests. The study, “Parkinsonian gait in elderly people: Significance of the threshold value of two and more falls per year,” was published in the…

Targeting certain regions of the alpha-synuclein protein could be a viable therapeutic strategy for Parkinson’s disease, a study suggests. The study, “Two C-terminal sequence variations determine differential neurotoxicity between human and mouse α-synuclein,” was published in the journal Molecular Neurodegeneration. Parkinson’s disease is characterized by…

Through a partnership, the Parkinson’s Foundation and Amazon’s Alexa cloud-based voice service are helping to make Parkinson’s (PD) education and resources available to more people. Alexa-enabled devices now cite Parkinson’s Foundation sources, in English or Spanish, when answering questions about the disease. Alexa is available on Amazon Echo…

Parkinson’s disease patients have an increased risk of dying from COVID-19, a recent study suggests. This heightened risk may be due to the development of pneumonia caused by the virus, a respiratory condition that is a leading cause of death in Parkinson’s patients. The study, “COVID-19 case fatality and Parkinson’s…

STADA Arzneimittel has announced the acquisition of Sweden-based Lobsor Pharmaceuticals, gaining the rights to its triple-combination therapy of levodopa, carbidopa, and entacapone, delivered via modern pump technology, as a treatment for patients with late-stage Parkinson’s disease. The triple-combo treatment has already been approved in most…

The investigational gene therapy AXO-Lenti-PD continues to be well-tolerated and to ease disease symptoms in people with Parkinson’s, new SUNRISE-PD trial data covering a second and higher dose patient group indicate. Parkinson’s disease is characterized by a gradual loss of the neurons in the brain that make dopamine, a neurotransmitter involved…

Oral Ongentys (opicapone) as a daily add-on treatment shortened overnight “off” periods and eased dyskinesia during “on” periods in people with Parkinson’s disease using levodopa, new analyses of Phase 3 clinical trial data show. Long-term use was also seen to lower patients’ average daily levodopa dose without worsening symptoms…

Kynmobi (apomorphine hydrochloride), a sublingual film to treat “off” episodes in people with Parkinson’s disease, is now available in the United States by prescription, its developer Sunovion announced. “People living with Parkinson’s disease can potentially spend hours each day navigating disruptions caused by off episodes, which may…